Open an account

Genmab A/S

GMAB · OMX

$43.79+$3.79 (+9.47%)TodayMarket closed ·
Prev close $40.00

About GMAB

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Employees
3,029
Headquarters
Valby
Listed
Oct 1, 2000
Sector
Health Care
Industry
Biotechnology
Website
genmab.com

GMAB key statistics

Market cap
158.62B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.47M
Volume
13.00M
Open price
$39.85
High today
$44.34
Low today
$39.64
52 Week high
$40.17
52 Week low
$23.62

Genmab A/S (GMAB) at a glance

Genmab A/S (GMAB) last traded at $43.79, with a market cap of 158.62B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $39.64 and $44.34. The current price is 10.5% above the day's low and 1.2% below its high.

Volume so far is 13.00M shares, above the average of 4.47M shares a day.

Over the past year Genmab A/S has ranged from $23.62 to $40.17, and now sits 122% of the way up that range.

Genmab A/S met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $4.91 per share against an estimate of $3.59.

The average analyst price target is $42.25, 3.5% below the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

88%of 8 analyst ratings say Buy
  • Buy87.5%
  • Hold12.5%
  • Sell0.0%
Price target · 21 analystsAvg $42.25
Low
$21.36
Now
$43.79
High
$63.43

GMAB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 56.5% on average.

  1. Q3 FY24: reported $2.92 per share against an estimate of $3.27
  2. Q4 FY24: reported $8.53 per share against an estimate of $3.63
  3. Q1 FY25: reported $3.05 per share against an estimate of $2.04
  4. Q2 FY25: reported $5.42 per share against an estimate of $4.33
  5. Q3 FY25: reported $6.46 per share against an estimate of $4.74
  6. Q4 FY25: reported $2.13 per share against an estimate of $3.50
  7. Q1 FY26: reported $0.83 per share against an estimate of $1.41
  8. Q2 FY26: reported $4.91 per share against an estimate of $3.59

GMAB news

  • Press releaseBusiness Wire

    Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

  • Press releasePRNewswire

    Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

  • Press releasePRNewswire

    AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

  • Press releaseBusiness Wire

    Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

  • Press releaseGlobe Newswire

    Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

  • Press releaseBusiness Wire

    Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

  • Press releaseBusiness Wire

    Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  • Press releaseBusiness Wire

    Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Similar companies

Companies in the same industry as Genmab A/S

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.